Drug Use Investigation of Regorafenib/STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy

Trial Profile

Drug Use Investigation of Regorafenib/STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 May 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 20 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2021.
    • 20 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2021.
    • 19 Jan 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top